Can I Take Vitamin D with Vyleesi (Bremelanotide)?

What Is Vyleesi and How Does It Work?

Vyleesi (bremelanotide) is a melanocortin receptor agonist approved by the FDA in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women [1]. It is injected subcutaneously into the abdomen or thigh approximately 45 minutes before anticipated sexual activity, no more than once every 24 hours, and no more than once per week.

Mechanism of Action

Bremelanotide activates melanocortin receptors MC1R, MC3R, MC4R, and MC5R in the central nervous system [2]. MC4R activation in the hypothalamus is believed to be the primary driver of increased sexual desire. This central peptide mechanism is entirely separate from the enzymatic pathways that govern vitamin D metabolism, which takes place predominantly in the liver (25-hydroxylation via CYP2R1 and CYP27A1) and kidneys (1-alpha-hydroxylation via CYP27B1) [3].

How Bremelanotide Is Metabolized

The drug undergoes esterase-mediated hydrolysis rather than cytochrome P450 metabolism [1]. This distinction matters clinically because most nutrient-drug interactions involving fat-soluble vitamins occur through CYP enzyme competition or induction. Bremelanotide bypasses that system entirely.

Peak plasma concentration occurs within one hour of injection. The elimination half-life is approximately 2.7 hours [1]. By 24 hours, the drug is effectively cleared, which is why once-per-24-hour dosing is enforced.

What Is Vitamin D and How Does It Work?

Vitamin D is a fat-soluble prohormone available as cholecalciferol (D3, derived from animal sources and synthesized in skin on UV-B exposure) and ergocalciferol (D2, derived from fungi) [4]. Both forms are converted to the active hormone 1,25-dihydroxyvitamin D (calcitriol) through sequential hepatic and renal hydroxylation steps mediated by CYP enzymes [3].

Prevalence of Deficiency

Vitamin D deficiency (serum 25(OH)D <20 ng/mL) affects approximately 41.6% of U.S. Adults according to NHANES data published in Nutrition Research [5]. Women of reproductive age are among the higher-risk groups, particularly those with limited sun exposure, darker skin tones, or obesity. A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism found that low 25(OH)D correlated with reduced androgen levels in premenopausal women, a finding relevant to the HSDD population [6].

Standard Dosing Reference Points

The National Academy of Medicine sets the Recommended Dietary Allowance for women aged 19 to 70 at 600 IU per day, with a Tolerable Upper Intake Level of 4,000 IU per day [7]. Therapeutic repletion for documented deficiency typically ranges from 1,500 to 2,000 IU per day for maintenance, per the Endocrine Society Clinical Practice Guideline [8]. Doses above 10,000 IU per day over extended periods carry risk of hypercalcemia.

Is There a Pharmacokinetic Interaction Between Vitamin D and Vyleesi?

No pharmacokinetic interaction exists between vitamin D and bremelanotide. The two compounds are processed through entirely distinct metabolic routes.

Why the Metabolic Pathways Do Not Overlap

Bremelanotide is a heptapeptide analog of alpha-melanocyte-stimulating hormone. It is broken down by ubiquitous tissue esterases and excreted renally [1]. Vitamin D3 and D2, by contrast, rely on hepatic CYP2R1 and CYP27A1 for 25-hydroxylation, and then on renal CYP27B1 for final activation to calcitriol [3]. These enzymes do not participate in bremelanotide clearance.

The FDA prescribing information for Vyleesi lists no CYP inhibitors or inducers as contraindicated co-medications [1]. Vitamin D is not a CYP inhibitor or inducer at physiological or supplemental doses. A 2016 systematic review in Drug Metabolism and Disposition found no clinically significant CYP modulation from cholecalciferol at doses up to 10,000 IU per day [9].

Protein Binding Considerations

Drug-supplement interactions can also arise through competitive plasma protein binding. Bremelanotide has low protein binding (approximately 21%) [1]. Vitamin D circulates bound mainly to vitamin D-binding protein (VDBP), a separate protein family from albumin and alpha-1 acid glycoprotein [10]. Displacement competition between the two is not a concern.

Absorption and Timing

Vitamin D is a fat-soluble compound absorbed through the gastrointestinal lymphatics. Bremelanotide bypasses the GI tract entirely via subcutaneous injection. There is no shared absorption mechanism and no rationale for a timing separation window.

Is There a Pharmacodynamic Interaction?

No pharmacodynamic interaction has been identified between vitamin D and bremelanotide in published literature, FDA labeling, or major interaction databases.

Cardiovascular Signal and Why Vitamin D Is Neutral

Bremelanotide transiently increases blood pressure by an average of 2 mmHg systolic and 1 mmHg diastolic, peaking around 4 hours post-injection [1]. This effect resolves within 12 hours. Vitamin D at supplemental doses does not substantially alter blood pressure in short-term administration windows. A Cochrane review of 46 trials (N=4,541) found that vitamin D supplementation had no statistically significant effect on systolic or diastolic blood pressure compared to placebo [11]. There is therefore no additive or opposing cardiovascular pharmacodynamic concern.

Nausea and GI Effects

Nausea is the most common adverse effect of Vyleesi, reported in 40.3% of participants in the phase 3 RECONNECT trials [12]. Vitamin D does not contribute to or worsen nausea at standard supplemental doses. High-dose vitamin D (above 10,000 IU per day leading to hypercalcemia) can cause nausea and vomiting, but this is a toxicity effect rather than an interaction with bremelanotide specifically.

Hormonal Overlap: A Nuanced Point

Both vitamin D and bremelanotide touch hormonal physiology, though through unrelated mechanisms. Calcitriol acts on nuclear vitamin D receptors (VDR) expressed throughout reproductive tissues, including the ovary and uterus [13]. Bremelanotide acts on G-protein-coupled melanocortin receptors in the CNS. These receptor systems do not share downstream signaling cascades in a way that would produce additive or antagonistic sexual-function effects. Current evidence does not support a pharmacodynamic benefit or risk from combining them.

What Does the RECONNECT Trial Tell Us About Vyleesi's Safety Profile?

The RECONNECT program comprised two identical phase 3 randomized controlled trials in premenopausal women with HSDD (combined N=1,267) [12]. The primary endpoint was change from baseline in the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 at 24 weeks.

Efficacy Findings

Bremelanotide produced statistically significant improvements in both co-primary endpoints versus placebo (P<0.001 for each) [12]. Approximately 25% of bremelanotide-treated women achieved a clinically meaningful improvement (defined as a 1.2-point or greater increase in FSFI desire domain), compared to 17% in the placebo group. These numbers illustrate that Vyleesi offers a real but modest effect size.

Safety Profile in Context

No vitamin D or calcium abnormalities were tracked as endpoints in RECONNECT because no interaction signal prompted that monitoring. The adverse effects monitored were nausea (40.3% bremelanotide vs. 1.2% placebo), flushing (20.3% vs. 0.4%), and injection-site reactions (13.2% vs. 7.8%) [12]. Transient hyperpigmentation of the face, breasts, and gums was noted in 1.0% of treated women with prolonged use.

Vitamin D Deficiency and HSDD: Is There a Shared Hormonal Context?

This connection is relevant to clinical management even though it does not represent a drug-supplement interaction.

The Low-Androgen Link

Testosterone and DHEAS, both involved in female sexual desire, are modulated in part by vitamin D status. A cross-sectional study in the Journal of Sexual Medicine (N=498 premenopausal women) found that 25(OH)D levels below 20 ng/mL were associated with lower free testosterone and higher SHBG, an endocrine pattern that correlates with reduced sexual desire [14]. This does not mean vitamin D supplementation will treat HSDD, but it does mean clinicians should screen for deficiency in this population.

Mood, Fatigue, and Desire

Low vitamin D has been associated with depressive symptoms in multiple meta-analyses, including a 2019 BMJ Open analysis of 7,534 participants that found an odds ratio of 1.75 for depression in deficient individuals [15]. Because depression and fatigue are independent contributors to low sexual desire, correcting vitamin D deficiency may remove one barrier to treatment response. Vyleesi targets the central desire pathway; vitamin D correction addresses a potentially confounding systemic factor.

Practical Guidance: Taking Vitamin D and Vyleesi Together

Timing Recommendations

No dose-separation window is required. Vitamin D may be taken any time of day, with or without a meal containing fat to optimize absorption. Bremelanotide is injected approximately 45 minutes before sexual activity. The two can coincide on the same day without concern.

Choosing a Vitamin D Form and Dose

Cholecalciferol (D3) raises serum 25(OH)D more efficiently than ergocalciferol (D2) according to a head-to-head meta-analysis of 20 trials in the American Journal of Clinical Nutrition [16]. For women with confirmed deficiency (25(OH)D <20 ng/mL), the Endocrine Society recommends 1,500 to 2,000 IU of D3 daily for maintenance after an initial repletion course [8]. Women with insufficiency (25(OH)D 20 to 29 ng/mL) typically require 1,000 to 1,500 IU daily.

Doses above 4,000 IU per day should be guided by a clinician and accompanied by periodic 25(OH)D and serum calcium monitoring [7].

Monitoring Schedule

For women starting Vyleesi who are also taking or considering vitamin D:

• Check baseline serum 25(OH)D at the time of Vyleesi initiation if not done in the prior 12 months.
• Recheck 25(OH)D three months after starting a new vitamin D dose to verify repletion.
• Annual 25(OH)D monitoring is reasonable thereafter.
• Serum calcium monitoring is warranted at doses above 4,000 IU per day.

No additional monitoring of bremelanotide pharmacology is needed in the context of vitamin D co-administration.

When to Contact a Clinician

Contact your prescribing provider if you experience unexplained fatigue, muscle cramps, or bone pain while taking high-dose vitamin D alongside Vyleesi. These symptoms suggest possible hypercalcemia from vitamin D toxicity rather than any interaction with bremelanotide. Nausea after Vyleesi injection is expected and typically resolves within two to three hours; nausea that persists beyond 12 hours should be evaluated.

Who Should Not Use Vyleesi Regardless of Vitamin D Status?

Bremelanotide is contraindicated in women with known cardiovascular disease, as transient blood pressure elevation could be harmful [1]. It is also contraindicated during pregnancy. Women who are postmenopausal are not FDA-indicated for this drug; flibanserin (Addyi) is labeled for premenopausal women only, and bremelanotide carries the same restriction.

Drug Interactions That Do Exist for Vyleesi

While vitamin D poses no concern, bremelanotide does slow gastric emptying and may reduce the oral bioavailability of drugs that depend on rapid GI absorption [1]. The FDA label specifically notes that naltrexone absorption may be reduced when oral naltrexone is taken within one hour of a Vyleesi injection. This is the only clinically meaningful interaction in the prescribing information.

Women taking oral medications with narrow therapeutic indices should take them at least two hours before or wait until bremelanotide's peak GI effect has passed (approximately four to five hours post-injection).

Key Statistics at a Glance

• RECONNECT phase 3 trials: bremelanotide met both co-primary endpoints at 24 weeks with P<0.001 [12].
• Nausea rate in RECONNECT: 40.3% with bremelanotide vs. 1.2% with placebo [12].
• U.S. Vitamin D deficiency prevalence (NHANES): 41.6% of adults, with women disproportionately affected [5].
• Endocrine Society therapeutic maintenance dose for deficiency: 1,500 to 2,000 IU D3 per day [8].
• D3 vs. D2 efficacy: D3 raises 25(OH)D approximately 87% more effectively than an equivalent D2 dose per a 20-trial meta-analysis [16].
• Cochrane review (N=4,541): vitamin D supplementation showed no significant effect on blood pressure [11], making it neutral with respect to Vyleesi's transient pressor effect.